To view the complete article click here (pdf format)

Interventions aimed at improving physical activity (PA) levels in cancer patients have been established as safe and generally well tolerated both during and after cancer treatments, providing numerous benefits, and perhaps extending survival.^1,2 PA guidelines for exercise testing and prescription in adult survivors of breast, prostate, colon, hematologic and gynecologic cancers have been published.³

Although lung cancer (LC) is the second most common malignancy, guidelines do not include this patient population. Emerging data suggest PA benefits both as an exercise-based physiologic assessment during evaluation for resection and as a complementary approach to reproduce benefits observed in other cancer and chronic lung disease populations.^1,4,5 PA interventions must be tailored to 3 distinct clinical settings: 1) resectable disease, 2) unresectable locally advanced disease and 3) metastatic disease.

Sponsorship of distribution of the Lung Cancer UPDATE Part 1 supplement to Oncology Exchange’s November 2011 issue is funded by Boehringer Ingelheim Canada Ltd./Ltee.

To view the complete article click here (pdf format)